Prodrugs of anthracycline antibiotics suited for tumor-specific activation

Anti-Cancer Drug Design

Volumn 10, Issue 6, 1995, Pages 441-450

  Azoulay, M ^a   Florent, J C ^a   Monneret, C ^a   Gesson, J P ^a   Jacquesy, J C ^a   Tillequin, F ^a   Koch, M ^a   Bosslet, K ^a   Czech, J ^a   Hoffman, D ^a  

^a INSTITUT CURIE   (France)

Author keywords

Carbamate; Doxorubicin; Enzyme; Prodrugs

Indexed keywords

ALPHA GALACTOSIDASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; MONOCLONAL ANTIBODY; PRODRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG HYDROLYSIS; DRUG SPECIFICITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ALPHA-GALACTOSIDASE; ANIMAL; ANTIBIOTICS, ANTHRACYCLINE; DOXORUBICIN; GALACTOSIDES; LEUKEMIA L1210; PRODRUGS; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028844549     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)